RAS Program at FNL

RAS计划是一项有针对性的计划，目的是在弗雷德里克国家癌症研究实验室(FNLCR)的支持下，开发针对RAS信号异常(特别是由于RAS基因突变)驱动的癌症的治疗策略。弗雷德里克国家癌症研究实验室是卫生与公众服务部唯一由联邦政府资助的研究和开发中心(FFRDC)。据设想，该计划将是一个中心和辐条模式，科学领先者、核心设施和重要技术位于FNLCR中心，研究由公司、学术机构和NCI内部研究计划的研究人员领导。在2014财年，有五个针对这些癌症的项目正在开发中。这笔支出用于购置资本设备，以便在FNLCR开展实验室研究。

The RAS Program is a targeted plan to develop therapeutic strategies against cancers driven by abnormal RAS signaling, especially as a consequence of RAS gene mutations, under the auspices of the Frederick National Laboratory for Cancer Research (FNLCR), the only Federally Funded Research and Development Center (FFRDC) in the Department of Health and Human Services. It is envisioned that the program will be a hub and spoke model, with scientific leaders, core facilities and important technologies at the FNLCR hub, and research led by investigators at companies, academic institutions and the NCI intramural research program at the spokes. There are five projects currently under development in FY14 to target these cancers. This expenditure is for the purpose of capital equipment to carry out laboratory research at FNLCR.